Header Logo

Connection

CANDELARIA GOMEZ-MANZANO to Glioma

Back to Details
This is a "connection" page, showing publications CANDELARIA GOMEZ-MANZANO has written about Glioma.
CANDELARIA GOMEZ-MANZANO
Connection Strength
5.018
Glioma
  1. Targeting Innate Immunity in Glioma Therapy. Int J Mol Sci. 2024 Jan 12; 25(2).
    View in: PubMed
    Score: 0.414
  2. TIE2 Associates with Caveolae and Regulates Caveolin-1 To Promote Their Nuclear Translocation. Mol Cell Biol. 2017 Nov 01; 37(21).
    View in: PubMed
    Score: 0.268
  3. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget. 2016 Mar 29; 7(13):16146-57.
    View in: PubMed
    Score: 0.241
  4. Macrophage Ablation Reduces M2-Like Populations and Jeopardizes Tumor Growth in a MAFIA-Based Glioma Model. Neoplasia. 2015 Apr; 17(4):374-84.
    View in: PubMed
    Score: 0.225
  5. Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol. 2014 Aug; 16(8):1025-6.
    View in: PubMed
    Score: 0.214
  6. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014 Apr 30; 5(8):2208-20.
    View in: PubMed
    Score: 0.211
  7. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget. 2010 Dec; 1(8):700-709.
    View in: PubMed
    Score: 0.167
  8. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des. 2009; 15(4):353-64.
    View in: PubMed
    Score: 0.146
  9. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008 Dec; 10(6):940-5.
    View in: PubMed
    Score: 0.142
  10. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther. 2008 May; 7(5):794-6.
    View in: PubMed
    Score: 0.139
  11. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett. 2008 May 18; 263(2):157-63.
    View in: PubMed
    Score: 0.138
  12. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene. 2008 Feb 21; 27(9):1310-4.
    View in: PubMed
    Score: 0.133
  13. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res. 2006 Dec; 4(12):915-26.
    View in: PubMed
    Score: 0.126
  14. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia. 2006 May; 8(5):419-28.
    View in: PubMed
    Score: 0.121
  15. Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. 2024 Nov 14; 16(11).
    View in: PubMed
    Score: 0.110
  16. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology. 2004 Aug 10; 63(3):418-26.
    View in: PubMed
    Score: 0.108
  17. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol. 2024 08 05; 26(8):1509-1525.
    View in: PubMed
    Score: 0.108
  18. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene. 2004 Mar 11; 23(10):1821-8.
    View in: PubMed
    Score: 0.105
  19. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther. 2024 Mar 06; 32(3):722-733.
    View in: PubMed
    Score: 0.104
  20. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022 07; 10(7).
    View in: PubMed
    Score: 0.093
  21. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-8.
    View in: PubMed
    Score: 0.091
  22. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol. 2021 11 02; 23(11):1911-1921.
    View in: PubMed
    Score: 0.089
  23. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res. 2001 Sep 15; 61(18):6693-7.
    View in: PubMed
    Score: 0.088
  24. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg. 2022 Mar 01; 136(3):757-767.
    View in: PubMed
    Score: 0.088
  25. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol. 2001 Aug; 19(2):359-65.
    View in: PubMed
    Score: 0.087
  26. Antitumor immune response during glioma virotherapy. Neuro Oncol. 2019 09 06; 21(9):1087-1088.
    View in: PubMed
    Score: 0.076
  27. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019 05 28; 10(1):2235.
    View in: PubMed
    Score: 0.075
  28. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med. 1999 Jan; 3(1):81-5.
    View in: PubMed
    Score: 0.073
  29. Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Neurosurgery. 2018 11 01; 83(5):1050-1056.
    View in: PubMed
    Score: 0.072
  30. [Molecular control of the cellular cycle and apoptosis: new treatments for gliomas]. Neurologia. 1998 Aug-Sep; 13(7):349-55.
    View in: PubMed
    Score: 0.071
  31. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol. 2018 05 10; 36(14):1419-1427.
    View in: PubMed
    Score: 0.069
  32. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014; 9(5):e97407.
    View in: PubMed
    Score: 0.053
  33. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One. 2011; 6(11):e26740.
    View in: PubMed
    Score: 0.044
  34. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009 Oct; 9(5):422-7.
    View in: PubMed
    Score: 0.038
  35. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene. 2009 Jun 18; 28(24):2358-63.
    View in: PubMed
    Score: 0.037
  36. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther. 2008 Mar; 16(3):487-93.
    View in: PubMed
    Score: 0.034
  37. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15; 67(24):11499-504.
    View in: PubMed
    Score: 0.034
  38. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res. 2007 Sep 01; 67(17):8255-63.
    View in: PubMed
    Score: 0.033
  39. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther. 2007 Aug; 14(8):756-61.
    View in: PubMed
    Score: 0.033
  40. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1585-92.
    View in: PubMed
    Score: 0.031
  41. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther. 2006 May; 6(5):697-708.
    View in: PubMed
    Score: 0.030
  42. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia. 2005 Aug; 7(8):723-9.
    View in: PubMed
    Score: 0.029
  43. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 2005 Mar; 12(3):284-94.
    View in: PubMed
    Score: 0.028
  44. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia. 2005 Jan; 7(1):48-56.
    View in: PubMed
    Score: 0.028
  45. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003 May 07; 95(9):652-60.
    View in: PubMed
    Score: 0.025
  46. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci. 2003 May 01; 8:d577-88.
    View in: PubMed
    Score: 0.025
  47. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol. 2003 Jan; 53(1):109-17.
    View in: PubMed
    Score: 0.024
  48. Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int J Oncol. 2002 Nov; 21(5):1015-20.
    View in: PubMed
    Score: 0.024
  49. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med. 2022 06 30; 386(26):2471-2481.
    View in: PubMed
    Score: 0.023
  50. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol. 2001 Feb; 18(2):343-7.
    View in: PubMed
    Score: 0.021
  51. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000 Jan 06; 19(1):2-12.
    View in: PubMed
    Score: 0.020
  52. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res. 1999 Oct 10; 252(1):1-12.
    View in: PubMed
    Score: 0.019
  53. Targeting in gene therapy for gliomas. Arch Neurol. 1999 Apr; 56(4):445-8.
    View in: PubMed
    Score: 0.019
  54. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999 Feb 15; 59(4):895-900.
    View in: PubMed
    Score: 0.018
  55. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology. 1998 Nov; 51(5):1250-5.
    View in: PubMed
    Score: 0.018
  56. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med. 1998 Jun; 4(6):685-90.
    View in: PubMed
    Score: 0.018
  57. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol. 1998 Mar; 12(3):665-9.
    View in: PubMed
    Score: 0.017
  58. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene. 1997 Oct 23; 15(17):2049-57.
    View in: PubMed
    Score: 0.017
  59. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res. 2017 07 15; 77(14):3894-3907.
    View in: PubMed
    Score: 0.016
  60. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene. 1996 Oct 17; 13(8):1615-9.
    View in: PubMed
    Score: 0.016
  61. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996 Feb 15; 56(4):694-9.
    View in: PubMed
    Score: 0.015
  62. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 1996 Jan 04; 12(1):103-10.
    View in: PubMed
    Score: 0.015
  63. Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol. 2012; 797:111-25.
    View in: PubMed
    Score: 0.011
  64. Advances in translational research in neuro-oncology. Arch Neurol. 2011 Mar; 68(3):303-8.
    View in: PubMed
    Score: 0.010
  65. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes. 1995 Dec; 9(6):465-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.